Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
GLOBAL BIOENERGIES: GLOBAL BIOENERGIES and AUDI renew their partnership in renewable gasoline

2018-07-12 globenewswire
Evry (France), 12 July 2018 - Global Bioenergies (Euronext Growth: ALGBE) and Audi announced today the signing of a new agreement focused on the implementation of residue usage, preparation of a path to commercialization and engine testing of new blends.
GLLBF ALGBE

0
GLOBAL BIOENERGIES : GLOBAL BIOENERGIES et AUDI renouvellent leur partenariat sur l'essence renouvelable

2018-07-12 globenewswire
Évry (France), le 12 juillet 2018 - Global Bioenergies (Euronext Growth : ALGBE) et Audi ont annoncé aujourd'hui la signature d'un nouvel accord centré sur l'utilisation de résidus, la préparation du déploiement commercial et le test de nouveaux mélanges d'essence renouvelable.
GLLBF ALGBE

0
Global Bioenergies successfully moves its C3 process to Demo scale

2018-06-26 globenewswire
Evry (France), 26 June 2018 - Global Bioenergies (Euronext Growth: ALGBE) announces having reached a new milestone in scaling up its C3 process converting renewable resources into isopropanol and acetone. These two biobased compounds target large markets in the cosmetics and solvent segments. They can also be converted into polypropylene, a key component in the plastics industry, with market value exceeding 70 billion dollars.
GLLBF ALGBE

0
Global Bioenergies poursuit avec succès la mise à l'échelle du procédé C3 : première validation en démonstrateur

2018-06-26 globenewswire
Global Bioenergies poursuit avec succès la mise à l'échelle du procédé C3 : première validation en démonstrateur
GLLBF ALGBE

0
GLOBAL BIOENERGIES :Avancée majeure dans le programme ISOPROD

2018-06-21 globenewswire
Franchissement de la première étape clé du projet regroupant Global Bioenergies, IBN-One, Cristal Union et L'Oréal
GLLBF ALGBE

0
GLOBAL BIOENERGIES :Major progress for the ISOPROD programme

2018-06-21 globenewswire
Completion of the first key step of the joint Global Bioenergies, IBN-One, Cristal Union and L'Oréal project
GLLBF ALGBE

0
GLOBAL BIOENERGIES :PUBLICATION DU DOCUMENT DE REFERENCE

2018-04-30 globenewswire
Evry, le 30 avril 2018 - Global Bioenergies (Euronext Growth : ALGBE) annonce aujourd'hui la publication de son document de référence au 31 décembre 2017, lequel intègre les termes du rapport financier annuel.
GLLBF ALGBE

0
GLOBAL BIOENERGIES: 2017 FINANCIAL RESULTS

2018-04-18 globenewswire
Net loss for the Group of €14.25m in 2017, including a €2.2m amortisation of the demo plant, i.e. a burn rate of around €12m
GLLBF ALGBE

0
GLOBAL BIOENERGIES : RESULTATS ANNUELS AU 31 DECEMBRE 2017

2018-04-18 globenewswire
Perte nette du Groupe de 14,25 M€ sur l'exercice 2017, dont 2,2 M€ d'amortissement du démonstrateur, soit un burn rate d'environ 12 M€
GLLBF ALGBE

0
GLOBAL BIOENERGIES: JAHRESABSCHLUSS PER 31. DEZEMBER 2017

2018-04-18 globenewswire
Konzernverlust von 14,25 Mio. Euro im Jahr 2017, davon 2,2 Mio. Euro Abschreibung für die Demonstrationsanlage, was einer Cash-Burn Rate von rund 12 Mio. Euro entspricht.
GLLBF ALGBE

0
GLOBAL BIOENERGIES und SkyNRG kündigen Kooperation bei der ASTM-Zertifizierung eines auf Isobuten basierenden Umwandlungsprozesses für die Herstellung nachhaltigen Flugbenzins an

2018-04-17 globenewswire
Global Bioenergies und SkyNRG kündigen Kooperation bei der ASTM-Zertifizierung eines auf Isobuten basierenden Umwandlungsprozesses für die Herstellung nachhaltigen Flugbenzins an
GLLBF ALGBE

0
GLOBAL BIOENERGIES et SkyNRG annoncent leur collaboration sur la certification ASTM du bio-isobutène et de sa conversion en biocarburant aéronautique durable

2018-04-17 globenewswire
Global Bioenergies et SkyNRG annoncent leur collaboration sur la certification ASTM du bio-isobutène et de sa conversion en biocarburant aéronautique durable
GLLBF ALGBE

0
GLOBAL BIOENERGIES and SkyNRG announce their collaboration on ASTM-certification of a bio-isobutene feedstock and conversion process for the production of sustainable aviation fuel

2018-04-17 globenewswire
Global Bioenergies and SkyNRG announce their collaboration on ASTM-certification of a bio-isobutene feedstock and conversion process for the production of sustainable aviation fuel
GLLBF ALGBE

0
Audi Joins French Quest for Biofuels That Won't Challenge Food - Bloomberg

2018-04-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GLLBF CLZNY ALGBE CLZNF

0
NEW VIDEO BY GLOBAL BIOENERGIES: FIRST CAR DRIVING WITH GLOBAL BIOENERGIES' RENEWABLE GASOLINE

2018-04-11 globenewswire
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performance of its process, to operate its demo plant in Germany, and to prepare the first full-scale plant through a joint venture with Cristal Union, named IBN-One.
GLLBF ALGBE

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

3h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...